Logo

Sandoz Reports Results of Omnitrope (biosimilar- somatropin) in PATRO Children Study for the Treatment of Turner Syndrome

Share this
Sandoz Reports Results of Omnitrope (biosimilar- somatropin) in PATRO Children Study for the Treatment of Turner Syndrome

Sandoz Reports Results of Omnitrope (biosimilar- somatropin) in PATRO Children Study for the Treatment of Turner Syndrome

Shots:

  • The PATRO Children- post marketing surveillance study evaluates biosimilar rhGH (Omnitrope) vs reference rhGH (Genotropin) in 348 children with TS at 130 centers across EU. In this study- 81.6% were rhGH naïve- and 90.2% were prepubertal
  • The results demonstrated that the therapy was safe & effective in real-life clinical practice- was generally well tolerated with no unexpected safety signals.
  • Mean duration of treatment was 38.5mos.- 48.9% experienced AEs substantial height gains in prepubertal individuals aged 3+ yrs. Additionally- 49.4% of patients discontinued the study

| Ref: Centre for Biosimilar| Image: Reuters

Click here to­ read the full press release 

Tuba

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions